ApoER2 Antibody (YA4259)

Cell membrane; Single-pass type I membrane protein; Secreted

Tissue_specificity:It is primarily expressed in the brain and placenta. It is also expressed in platelets and megakaryocytes. It is not expressed in the liver.

Q14114 has 5 isomers: Q14114-1: 105634 Da (predicted); Q14114-2: 77845 Da (predicted); Q14114-3: 99092 Da (predicted); Q14114-4: 87959 Da (predicted); Q14114-5: Da (predicted).
O-glycosylated. Some alternatively spliced isoforms lack the O-linked sugar domain (By similarity);Undergoes sequential, furin and gamma-secretase dependent, proteolytic processing, resulting in the extracellular release of the entire ligand-binding domain as a soluble polypeptide and in the intracellular domain (ICD) release into the cytoplasm. The gamma-secretase-dependent proteolytical processing occurs after the bulk of the extracellular domain has been shed, in a furin-dependent manner, in alternatively spliced isoforms carrying the furin cleavage site. Hypoglycosylation (mainly hypo-O-glycosylation) leads to increased extracellular cleavage, which in turn results in accelerating release of the intracellular domain (ICD) by the gamma-secretase. The resulting receptor fragment is able to inhibit Reelin signaling and in particular the Reelin-induced DAB1 phosphorylation (By similarity);Tyrosine phosphorylated upon apoE binding;Ubiquitinated by MYLIP leading to degradation

Homooligomer (PubMed:30873003). Interacts with VLDLR (PubMed:30873003). Reelin associates with two or more receptor molecules (PubMed:20223215). Interacts with DAB1 and JNK-interacting proteins. Interacts with SNX17 (By similarity). Interacts with PCSK9. Interacts with MDK; this interaction is calcium dependent (By similarity). Interacts with CLU (PubMed:24381170)

Q14114

MCI1; LRP-8; APOER2; HSZ75190